HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on ORIC Pharmaceuticals and increased the price target from $15 to $21.
March 21, 2024 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ORIC Pharmaceuticals' Buy rating is maintained by HC Wainwright & Co., with the price target raised from $15 to $21.
The increase in price target from $15 to $21 by a reputable analyst firm like HC Wainwright & Co. signals a strong confidence in ORIC Pharmaceuticals' future performance. This endorsement is likely to positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100